L&T Technology Services Limited has announced the allotment of 2,025 equity shares under its Employee Stock Option Scheme 2016. The decision was approved by the company's Nomination & Remuneration Committee of the Board of Directors on March 16, 2026.

ESOP Allotment Details

The committee approved the share allotment through a resolution passed by circulation on March 16, 2026, at around 04:31 p.m. The allotment was made to grantees who had exercised their vested stock options under the company's Employee Stock Option Scheme, 2016.

Share Rights and Privileges

The newly allotted shares will rank pari-passu with the existing shares of the company in all respects. This means that the allotted shares will carry the same rights, privileges, and obligations as the existing equity shares, including voting rights, dividend entitlements, and other shareholder benefits.

Regulatory Compliance

The disclosure was made in compliance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015. The company has informed both the National Stock Exchange of India Limited and BSE Limited about this corporate action through proper regulatory channels.

L&T Technology Services has officially launched its next-generation AI-powered digital twin platform for lung navigation, surgical planning, and respiratory diagnostics. The platform represents a significant advancement in healthcare technology, combining the company's MedTech expertise with NVIDIA's AI infrastructure to deliver enhanced precision and improved clinical outcomes.

Advanced Technology Integration and Platform Capabilities

The comprehensive platform integrates directly with CT imaging workflows and leverages deep learning models to reconstruct detailed 3D digital twins of lungs. This technology enables clinicians to visualize critical anatomical structures including airways, blood vessels, lung lobes, and lesions in an immersive digital environment.

Clinical Applications and Surgical Planning

The scalable digital twin platform transforms static CT scans into dynamic, simulation-ready lung models. This capability allows clinicians to analyze anatomical relationships, plan surgical pathways, and navigate bronchoscopic procedures with enhanced accuracy. The framework supports advanced visualization, automated segmentation, volumetric analysis, and navigation path planning.

Leadership Perspectives and Market Impact

Amit Chadha, CEO & Managing Director of L&T Technology Services, emphasized the transformative potential of the platform: "By combining LTTS' engineering expertise in medical imaging and digital health platforms with the power of NVIDIA's Physical AI infrastructure, we are enabling a new generation of AI-powered biological digital twins for precision medicine. These platforms can transform how clinicians visualize lung anatomy, plan interventions and deliver precision care."

David Niewolny, Head of Business Development for Healthcare and Medical Technology at NVIDIA, highlighted the significance of digital twin technology: "Digital twins are emerging as a powerful new tool for precision medicine. By leveraging NVIDIA Physical AI infrastructure, Omniverse, MONAI and TensorRT, LTTS is transforming CT data into interactive lung digital twins that allow clinicians to visualize anatomy in 3D, simulate procedures and plan clinical interventions with greater confidence."

Healthcare Industry Transformation

With respiratory diseases such as lung cancer and COPD continuing to rise globally, AI-driven digital twin technologies are expected to accelerate the shift from traditional imaging interpretation toward predictive, simulation-driven, and minimally invasive intervention planning. This advancement enables more personalized and data-driven treatment pathways, positioning the platform at the forefront of precision medicine innovation.